Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10010943 | Journal of the American Academy of Dermatology | 2005 | 14 Pages |
Abstract
A variety of therapeutic options are available to treat psoriasis and atopic dermatitis (AD). Local agents typically are used to treat localized and milder forms of disease, whereas phototherapy and systemic agents are used for more generalized and severe disease. Various combinations and sequences of topical or systemic therapies, or both, have been utilized in the treatment of psoriasis and, less frequently, of AD. Conventional systemic therapies for psoriasis, such as corticosteroids, oral calcineurin inhibitors, antimetabolites, and retinoids, are limited by their propensity to cause serious side effects. More recently, a number of immunobiologic agents, such as monoclonal antibodies, recombinant cytokines, and fusion proteins, have been approved by the Food and Drug Administration or are undergoing development as systemic antipsoriatic treatments. In many of these categories, a number of exciting new therapies are in development that may augment the existing armamentarium available to clinicians for the treatment of inflammatory skin diseases.
Keywords
FDAICAMTCIIMPIFN-γIL-2RLFAAPCpsoralen plus ultraviolet ATCrUVBTh1, Th2UVATIGantigen-presenting cellLymphocyte Function-associated AntigenUltraviolet Aultraviolet Bimmunoglobulin interleukintumor necrosis factor alphaAtopic dermatitisFood and Drug AdministrationTNF-αmajor histocompatibility complexMHCtopical calcineurin inhibitorintracellular adhesion moleculeInosine monophosphatePuvaInterferon gammaInterleukin 2 receptorT-cell receptor
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Alice B. MD, PhD,